Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Ilaria Muller, PhD student, Cardiff University, on a possible common antigen between thyroid cancer and breast cancer. Muller says if this common antigen does exist, an immune therapy could hypothetically be developed to combat it and essentially combat both breast and thyroid cancer.
Muller sadds that in most forms of thyroid cancer, the thyroid can be removed and replacement treatments for its function can be taken. Muller and colleagues at Cardiff Univeristy are currently investigating the topic of thyroid autoimmunity as a biomarker of outcome in women with breast cancer by way of a large-scale study using data from the Taxotere As Adjuvant Chemotherapy (Tact) Trial (Cruk01/001).
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
April 18th 2024During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More